IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)

In Cohort 1, the study was intended to assess safety and efficacy of neoadjuvant combination of IPH5201 and durvalumab in addition to standard chemotherapy and adjuvant combination of IPH5201 and durvalumab, in untreated patients with resectable, early-stage (stage II to IIIA) non-small cell lung cancer (NSCLC). Study Design was updated following the results of interim analysis # 2 (protocol amendment, adding cohort 2). Cohort 2 includes patients with resectable Stage II to IIIB NSCLC expressing PD-L1 ≥1%, receiving (only) neoadjuvant IPH5201+ durvalumab + chemotherapy

Trial Details

NCT ID
NCT05742607
Phase
PHASE2
Sponsor
Innate Pharma
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • IPH5201 + durvalumab + standard chemotherapy
Locations (sample)
  • St. Petersburg, Florida, United States|27.77086,-82.67927
  • Tampa, Florida, United States|27.94752,-82.45843
  • Chicago, Illinois, United States|41.85003,-87.65005
  • Lake Success, New York, United States|40.77066,-73.71763
  • Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

  • Patients are eligible to be included in the study only if all of the following criteria apply:
  • Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the Informed Consent Form (IC…
  • Provision of signed and dated written ICF prior to any mandatory study specific procedures, sampling, and analyses - including collection of sample…
  • Patients must be ≥18 years at the time of screening.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →